Table 2.

Clinical trials of MSC in PD [97].

Title	Study Type	Study Design	No. of Participants	Route of Administration	Outcome Measures	Clinicaltrials.gov ID
To Study the Safety and Efficacy of Bone Marrow-Derived MSC Transplant in PD	Interventional	Single group assignment	5	Cerebral	Improvement in the clinical condition of the patient assessed using UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) and Time Tests.	NCT00976430
Phase I/II Trial of Autologous Bone Marrow-Derived MSC to Patients With PD.	Interventional	Single group assignment	20	Intravenous	Number of participants who experienced adverse effects	NCT01446614
Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial	Interventional	Randomized	25	Arterial	Incidence of adverse effects	NCT01824121
Pilot Phase I Study of Allogeneic Bone Marrow-Derived MSC Therapy for Idiopathic PD	Interventional	Non-randomized	20	Intravenous	safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy	NCT02611167
Safety and Efficacy Investigation of Patients With PD by Transplantation of Umbilical Cord Derived MSC	Interventional	Single group assignment	20	Intravenous	Changes of the Unified Parkinson's Disease Rating Scale (UPDRS)	NCT03550183
A Safety and Efficacy Study of the Effects of MSC (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With PD (PD).	Interventional	Randomized	10	Intrathecal and intravenous	Incidence of Treatment-Emergent Adverse Events (TAEAs) as a result of the injection	NCT03684122
Allogeneic Bone Marrow-derived MSC as a Disease-modifying Therapy for Idiopathic PD: Phase IIa Double-blind Randomized Placebo-Controlled Trial	Interventional	Randomized	45	Not defined	Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale	NCT04506073